Merck & Co. (MRK) : Advisory Services Network scooped up 21,328 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 7, 2016. The investment management firm now holds a total of 40,322 shares of Merck & Co. which is valued at $2,531,012.Merck & Co. makes up approximately 0.48% of Advisory Services Network’s portfolio.
Other Hedge Funds, Including , Stokes Hubbell Capital Management added MRK to its portfolio by purchasing 3,339 company shares during the most recent quarter which is valued at $209,589. Merck & Co. makes up approx 0.09% of Stokes Hubbell Capital Management’s portfolio.Summit Financial Wealth Advisors boosted its stake in MRK in the latest quarter, The investment management firm added 251 additional shares and now holds a total of 12,089 shares of Merck & Co. which is valued at $759,189. Merck & Co. makes up approx 0.33% of Summit Financial Wealth Advisors’s portfolio.New England Research Management reduced its stake in MRK by selling 24,202 shares or 63.48% in the most recent quarter. The Hedge Fund company now holds 13,922 shares of MRK which is valued at $874,302. Merck & Co. makes up approx 0.74% of New England Research Management’s portfolio.Telemus Capital reduced its stake in MRK by selling 440 shares or 1.29% in the most recent quarter. The Hedge Fund company now holds 33,705 shares of MRK which is valued at $2,116,674. Merck & Co. makes up approx 0.24% of Telemus Capital’s portfolio.Washington Trust Bank boosted its stake in MRK in the latest quarter, The investment management firm added 2,888 additional shares and now holds a total of 34,411 shares of Merck & Co. which is valued at $2,161,011. Merck & Co. makes up approx 0.52% of Washington Trust Bank’s portfolio.
Merck & Co. opened for trading at $62.77 and hit $62.99 on the upside on Friday, eventually ending the session at $62.77, with a gain of 0.18% or 0.11 points. The heightened volatility saw the trading volume jump to 1,07,75,249 shares. Company has a market cap of $173,572 M.
On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $0.91. The company had revenue of $9844.00 million for the quarter, compared to analysts expectations of $9782.80 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.86 EPS.
Many Wall Street Analysts have commented on Merck & Co.. Company shares were Reiterated by Barclays on Sep 9, 2016 to “Overweight”, Firm has raised the Price Target to $ 72 from a previous price target of $66 .Credit Suisse Upgraded Merck & Co. on Aug 8, 2016 to ” Outperform”, Price Target of the shares are set at $73.Company shares were Reiterated by Deutsche Bank on Aug 8, 2016 to “Hold”, Firm has raised the Price Target to $ 59 from a previous price target of $58 .
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.